[1]薛欣瑞 殷跃辉.肾传入神经在高血压中的调节作用[J].心血管病学进展,2022,(3):249-252.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
 XUE Xinrui,YIN Yuehui.Role of Afferent Renal Nerves in Hypertension Regulation[J].Advances in Cardiovascular Diseases,2022,(3):249-252.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
点击复制

肾传入神经在高血压中的调节作用()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年3期
页码:
249-252
栏目:
综述
出版日期:
2022-03-25

文章信息/Info

Title:
Role of Afferent Renal Nerves in Hypertension Regulation
文章编号:
202110099
作者:
薛欣瑞1 殷跃辉 2
(1.重庆医科大学研究生院,重庆 400010;2.重庆医科大学附属第二医院心血管内科,重庆 400010)
Author(s):
XUE Xinrui1YIN Yuehui2
(1.Chongqing Medical University Graduate School,Chongqing 400010,China; 2.Department of Cardiology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
关键词:
肾去神经术高血压肾传入神经
Keywords:
Renal denervationHypertensionAfferent renal nerve
DOI:
10.16806/j.cnki.issn.1004-3934.2022.03.000
摘要:
交感神经系统的过度激活与高血压密切相关。肾去神经术通过消融肾传入神经和肾传出神经来降低交感神经活性,已成为一种新的高血压治疗方法。肾传出神经对血压的调控已得到了广泛的研究,但对肾传入神经在血压中的调节作用认知相对不足,现拟对此进行简要综述。
Abstract:
Hyperactivation of sympathetic nervous system is closely related to hypertension. Renal denervation has become a new treatment for hypertension by ablating renal afferent nerve and renal efferent nerve to reduce sympathetic nerve activity. The regulation of efferent renal nerves on blood pressure has been widely studied,but the cognition of the regulation of afferent renal nerves in blood pressure is relatively insufficient. So,this paper intends to make a review of this

参考文献/References:

[1]Osborn JW,Foss JD. Renal nerves and long-term control of arterial pressure[J]. Compr Physiol,2017,7(2):263-320.

[2]Ferguson M,Bell C. Substance P-immunoreactive nerves in the rat kidney[J]. Neurosci Lett,1985,60(2):183-188.

[3]Knight DS,Cicero S,Beal JA. Calcitonin gene-related peptide-immunoreactive nerves in the rat kidney[J]. Am J Anat,1991,190(1):31-40.

[4]Xie C,Sachs JR,Wang DH. Interdependent regulation of afferent renal nerve activity and renal function:role of transient receptor potential vanilloid type 1,neurokinin 1,and calcitonin gene-related peptide receptors[J]. J Pharmacol Exp Ther,2008,325(3):751-757.

[5]Gontijo JR,Smith LA,Kopp UC. CGRP activates renal pelvic substance P receptors by retarding substance P metabolism[J]. Hypertension,1999,33(1 Pt 2):493-498.

[6]Xie C,Wang DH. Ablation of transient receptor potential vanilloid 1 abolishes endothelin-induced increases in afferent renal nerve activity:mechanisms and functional significance[J]. Hypertension,2009,54(6):1298-1305.

[7]Foss JD,Wainford RD,Engeland WC,et al. A novel method of selective ablation of afferent renal nerves by periaxonal application of capsaicin[J]. Am J Physiol Regul Integr Comp Physiol,2015,308(2):R112-R122.

[8]Kopp UC,Olson LA,DiBona GF. Renorenal reflex responses to mechano- and chemoreceptor stimulation in the dog and rat[J]. Am J Physiol,1984,246(1 Pt 2):F67-F77.

[9]Frame AA,Carmichael CY,Kuwabara JT,et al. Role of the afferent renal nerves in sodium homeostasis and blood pressure regulation in rats[J]. Exp Physiol,2019,104(8):1306-1323.

[10] Stella A,Zanchetti A. Functional role of renal afferents[J]. Physiol Rev,1991,71(3):659-682.

[11]Katholi RE,Hageman GR,Whitlow PL,et al. Hemodynamic and afferent renal nerve responses to intrarenal adenosine in the dog[J]. Hypertension,1983,5(2 Pt 2):I149-I154.

[12]Smits JF,Brody MJ. Activation of afferent renal nerves by intrarenal bradykinin in conscious rats[J]. Am J Physiol,1984,247(6 Pt 2):R1003-R1008.

[13]Barry EF,Johns EJ. Intrarenal bradykinin elicits reno-renal reflex sympatho-excitation and renal nerve-dependent fluid retention[J]. Acta Physiol(Oxf),2015,213(3):731-739.

[14]Ye C,Qiu Y,Zhang F,et al. Chemical stimulation of renal tissue induces sympathetic activation and a pressor response via the paraventricular nucleus in rats[J]. Neurosci Bull,2020,36(2):143-152.

[15]Zheng F,Ye C,Wan GW,et al. Interleukin-1β in hypothalamic paraventricular nucleus mediates excitatory renal reflex[J]. Pflugers Arch,2020,472(11):1577-1586.

[16]Zheng H,Patel KP. Integration of renal sensory afferents at the level of the paraventricular nucleus dictating sympathetic outflow[J]. Auton Neurosci,2017,204:57-64.

[17]Haselton JR,Goering J,Patel KP. Parvocellular neurons of the paraventricular nucleus are involved in the reduction in renal nerve discharge during isotonic volume expansion[J]. J Auton Nerv Syst,1994,50(1):1-11.

[18]Zhou JJ,Ma HJ Shao JY,et al. Impaired hypothalamic regulation of sympathetic outflow in primary hypertension[J]. Neurosci Bull,2019,35(1):124-132.

[19]Chen HH,Cheng PW,Ho WY,et al. Renal denervation improves the baroreflex and GABA system in chronic kidney disease-induced hypertension[J]. Sci Rep,2016,6:38447.

[20]Milanez MIO,Veiga AC,Martins BS,et al. Renal sensory activity regulates the γ-aminobutyric acidergic inputs to the paraventricular nucleus of the hypothalamus in goldblatt hypertension[J]. Front Physiol,2020,11:601237.

[21]Patel KP,Xu B,Liu X,et al. Renal denervation improves exaggerated sympathoexcitation in rats with heart failure:a role for neuronal nitric oxide synthase in the paraventricular nucleus[J]. Hypertension,2016,68(1):175-184.

[22]Zheng H,Katsurada K,Liu X,et al. Specific afferent renal denervation prevents reduction in neuronal nitric oxide synthase within the paraventricular nucleus in rats with chronic heart failure[J]. Hypertension,2018,72(3):667-675.

[23]Frame AA,Carmichael CY,Wainford RD. Renal afferents[J]. Curr Hypertens Rep,2016,18(9):69.

[24]Ryan MJ. An update on immune system activation in the pathogenesis of hypertension[J]. Hypertension,2013,62(2):226-230.

[25]Veelken R,Vogel EM,Hilgers K,et al. Autonomic renal denervation ameliorates experimental glomerulonephritis[J]. J Am Soc Nephrol,2008,19(7):1371-1378.

[26]Trott DW,Harrison DG. The immune system in hypertension[J]. Adv Physiol Educ,2014,38(1):20-24.

[27]Banek CT,Knuepfer MM,Foss JD,et al. Resting afferent renal nerve discharge and renal inflammation:elucidating the role of afferent and efferent renal nerves in deoxycorticosterone acetate salt hypertension[J]. Hypertension,2016,68(6):1415-1423.

[28]Xiao L,Kirabo A,Wu J,et al. Renal denervation prevents immune cell activation and renal inflammation in angiotensinⅡ-induced hypertension[J]. Circ Res,2015,117(6):547-557.

[29]Ong J,Kinsman BJ,Sved AF,et al. Renal sensory nerves increase sympathetic nerve activity and blood pressure in 2-kidney 1-clip hypertensive mice[J]. J Neurophysiol,2019,122(1):358-367.

[30]Wyss JM,Aboukarsh N,Oparil S. Sensory denervation of the kidney attenuates renovascular hypertension in the rat[J]. Am J Physiol,1986,250(1 Pt 2):H82-H86.

[31]Oparil S,Sripairojthikoon W,Wyss JM. The renal afferent nerves in the pathogenesis of hypertension[J]. Can J Physiol Pharmacol,1987,65(8):1548-1558.

[32]Veiga AC,Milanez MIO,Ferreira GR,et al. Selective afferent renal denervation mitigates renal and splanchnic sympathetic nerve overactivity and renal function in chronic kidney disease-induced hypertension[J]. J Hypertens,2020,38(4):765-773.

[33]Foss JD,Fink GD,Osborn JW. Differential role of afferent and efferent renal nerves in the maintenance of early- and late-phase Dahl S hypertension[J]. Am J Physiol Regul Integr Comp Physiol,2016,310(3):R262-R267.

[34]Hering D,Marusic P,Walton AS,et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension[J]. Hypertension,2014,64(1):118-124.

[35]Kandzari DE,B?hm M,Mahfoud F,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J]. Lancet,2018,391(10137):2346-2355.

[36]Weber MA,Kirtane AJ,Weir MR,et al. The REDUCE HTN:REINFORCE:randomized,sham-controlled trial of bipolar radiofrequency renal denervation for the treatment of hypertension[J]. JACC Cardiovasc Interv,2020,13(4):461-470.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
 SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
 FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
 CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(3):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
 ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
 ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
 HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(3):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
 ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(3):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
 LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
 WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(3):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]

备注/Memo

备注/Memo:
通信作者:殷跃辉,E-mail:Yinyh@hospital.cqmu.edu.cn

收稿日期:2021-10-25

更新日期/Last Update: 2022-04-20